Tempura,
I have no issue with contrary views ...everyone is entitled to their opinion
But your reasoning is ridiculously flawed
So you think there will be no substantial rerating on successful phase 2 trials
''The only thing that will move it substantially is if they license some product and what are the odds of that before phase 3 is reached?''
Go do some research on the amount of companies who have been bought out for 100s of millions even before phase 2 trials
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX, page-40
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
-0.015(3.19%) |
Mkt cap ! $250.3M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 49.0¢ | 45.5¢ | $1.515M | 3.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 161532 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 33998 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |